Infectious Disease Special Edition news story
Patients treated with bictegravir, emtricitabine, and tenofovir alafenamide (B/FTC/TAF; Biktarvy, Gilead Sciences) report improved overall health during the course of treatment, even if they had preexisting comorbidities before starting therapy, according to findings from the BICSTaR study presented at HIV Glasgow 2026 (abstract 094).
Treatment-naive participants who underwent rapid initiation of B/FTC/TAF reported worse overall mental and physical health at the beginning of treatment compared with others in the study, but saw faster improvements based on the measures used across 24 months of treatment, the researchers reported.
In addition, improvements on scores of physical health were more pronounced (albeit from a lower baseline) among participants with more advanced HIV (CD4+ <200 cells/mcL and viral load >100,000 copies/mL) compared with other groups, they said.
Read the full news story here.
/free registration is required/
View all Infectious Disease Special Edition reports from HIV Glasgow 2026
Source : Infectious Disease Special Edition
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.